Clinical Trial

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD1613 in healthy participants, including Japanese and Chinese descent.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-05-28; most recent amendment 2026-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT06995820
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Healthy
Enrollment 136 participants
Start Date 2025-06-06
Primary Completion 2026-09-23 (estimated)
Study Completion 2026-09-23 (estimated)
Updated on ClinicalTrials.gov 2026-05-15